Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Children's interstitial and diffuse lung disease.

Steve Cunningham1, Adam Jaffe2, Lisa R Young3

  • 1Paediatric Respiratory Medicine, Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.

The Lancet. Child & Adolescent Health
|June 23, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Evolving Epidemiology of Invasive Pneumococcal Disease in Australian Children: A Multicentre Retrospective Observational Study.

Open forum infectious diseases·2026
Same author

Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON.

Pediatric pulmonology·2026
Same author

Long-Lived Photochromism in a Crystalline Hybrid Naphthalenediimide-Polyoxovanadate System.

Inorganic chemistry·2026
Same author

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations.

Trials·2026
Same author

Respiratory Outcomes in Children With Neonatal Respiratory Distress Syndrome and Monoallelic ABCA3 Variants.

Pediatric pulmonology·2026
Same author

Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same journal

How interactional AI may alter adolescent relational learning and mental health.

The Lancet. Child & adolescent health·2026
Same journal

Prioritising pregnant and parenting adolescents in the HIV and SRHR response.

The Lancet. Child & adolescent health·2026
Same journal

Unleash the synergies: children's rights and the new strategy for child and adolescent health in Europe and Central Asia.

The Lancet. Child & adolescent health·2026
Same journal

Children and adolescents in the humanitarian response.

The Lancet. Child & adolescent health·2026
Same journal

Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial.

The Lancet. Child & adolescent health·2026
Same journal

The Phoenix criteria for paediatric sepsis: 2 years on.

The Lancet. Child & adolescent health·2026
See all related articles

Children's interstitial and diffuse lung disease (chILD) is rare and hard to diagnose. International collaboration and genetic insights are key to advancing treatments for these over 200 lung conditions.

Area of Science:

  • Pediatric Pulmonology
  • Rare Diseases
  • Genetics

Background:

  • Children's interstitial and diffuse lung disease (chILD) comprises over 200 rare conditions.
  • Symptoms often mimic common ailments, complicating diagnosis and treatment.
  • Current empirical therapies are limited and carry risks, especially for infants.

Purpose of the Study:

  • To highlight the challenges in diagnosing and treating chILD.
  • To emphasize the need for international collaboration in chILD research.
  • To discuss the evolving role of genetics and novel therapeutics in chILD.

Main Methods:

  • Review of current clinical practices and research in chILD.
  • Analysis of the impact of genetics on chILD diagnosis and classification.

Related Experiment Videos

  • Assessment of existing and emerging therapeutic strategies for chILD.

    • Main Results:

    • Clinical collaborations are improving diagnostic accuracy and understanding of chILD.
    • Genetics is increasingly vital for accurate chILD diagnosis and may align classification systems.
    • Novel therapeutics show promise, but validated outcome measures are urgently needed.

    Conclusions:

    • Greater international collaboration is essential to address knowledge gaps in chILD.
    • Advancements in genetics and targeted therapies offer hope for chILD patients.
    • Development of reliable outcome measures is critical for future chILD research and treatment.